Dora L. Vallejo – Ardila, Senior Medical Monitor/ Clinical Research Physician at Avance Clinical, shared a post on LinkedIn:
“Thrilled to see such an inspiring advance presented at SITC2025, the first in human trial of in vivo CAR myeloid cell therapy for solid tumors.
Dr. Rasha Cosman and colleagues at The Kinghorn Cancer Centre St. Vincent’s Hospital (Darlinghurst, Australia), shared early results from the Phase 1 study of MT 302, an mRNA LNP therapy targeting TROP2.
- In 27 patients with advanced, heavily pretreated solid tumors spanning 11 cancer types, MT 302 showed a manageable safety profile and encouraging signs of activity.
- Cytokine release syndrome was mild and reversible, and only one high grade neurotoxicity event occurred at the top dose. Among patients with measurable disease, one achieved a confirmed partial response lasting 16 months, and several others had durable disease stabilization.
- Mechanistic data were equally exciting: MT 302 drove the recruitment of myeloid CAR cells into tumor sites, triggered proinflammatory gene expression, and enhanced T cell infiltration, reshaping the tumor microenvironment in ways we have long hoped to achieve.
Congratulations to Dr. Cosman and the entire team for this pioneering work. The ability to generate CAR cells in vivo could open new doors for treating solid tumors and broaden access to cell therapies worldwide.”
More from Dora L. Vallejo – Ardila on OncoDaily.